Adynamic bone in patients with chronic kidney disease.
Adynamic bone in patients with chronic kidney disease (CKD) is a clinical concern because of its potential increased risk for fracture and cardiovascular disease (CVD). Prevalence rates for adynamic bone are reportedly increased, although the variance for its prevalence and incidence is large. Differences in its prevalence are largely attributed to classification and population differences, the latter of which constitutes divergent groups of elderly patients having diabetes and other comorbidities that are prone to low bone formation. Most patients have vitamin D deficiency and the active form, 1,25-dihydroxyvitamin D, invariably decreases to very low levels during CKD progression. Fortunately, therapy with vitamin D receptor activators (VDRAs) appears to be useful in preventing bone loss, in part, by its effect to stimulate bone formation and in decreasing CVD morbidity, and should be considered as essential therapy regardless of bone turnover status. Future studies will depend on assessing cardiovascular outcomes to determine whether the risk/reward profile for complications related to VDRA and CKD is tolerable.
Andress
D L
DL
Division of Nephrology, University of Washington, Seattle, Washington, USA. dennis.andress@abbott.com
D017209:Apoptosis; D001847:Bone Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D002908:Chronic Disease; D006801:Humans; D007674:Kidney Diseases / Q000150:complications*; D010006:Osteoblasts / Q000473:pathology; D010012:Osteogenesis; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors